Myc is an oncoprotein transcription factor that features prominently in a variety of human cancers. Indeed, it is estimated that approximately one-third of all cancer deaths in the United States involve inappropriate Myc expression or activity. Cells have evolved a number of mechanisms to restrict Myc expression in normal cells, one of which is ubiquitin (Ub)-mediated proteolysis. The importance of Myc destruction is evidenced by the fact that cancer-associated mutations within Myc block its destruction and potently enhance its oncogenic activity. The goal of this proposal is to understand the mechanisms and consequences of the destruction of Myc by the Ub-proteasome system.
Four Specific Aims are proposed.
Aim 1 will investigate the mechanisms through which Myc stability is regulated. Much of this analysis will focus on the identification and characterization of proteins that interact with a central element within Myc that is important for its post- ubiquitylation destruction.
Aim 2 is focused on understanding how the adenoviral oncoprotein E1A stabilizes Myc, and the contribution of this activity to E1A's oncogenic capabilities.
In Aim 3, the emphasis will shift to analysis of a highly-conserved, but little-studied, element in Myc that is important for Myc turnover and contributes to oncogenic transformation by dampening the ability of Myc to induce apoptosis. Finally, in Aim 4, the activity of a number of tumor-derived, stable, Myc mutants will be studied in detail to learn the mechanisms though which Myc function is perturbed in cancer. These studies make extensive use of cell based assays, RNAi, microarray experiments, proteomic analyses, as well as cutting-edge mouse models of lymphomagenesis, hepatocellular carcinoma, and breast cancer. Because the Ub-proteasome system is emerging as an attractive target for anti-tumor therapies, understanding how and why Myc is destroyed offers the potential to reveal new strategies for treating human cancer.
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348 |
Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983 |
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8 |
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res : |
On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139 |
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381 |
Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368 |
Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114 |
Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277 |
Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6 |
Showing the most recent 10 out of 610 publications